![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Herborium Group Inc (PK) | USOTC:HBRM | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 2,980 | 01:00:00 |
Shareholders can participate on Wednesday, November 3, 2010, by dialing (805) 309-0111 and entering access code 646614, up to 10 minutes before the call, beginning at 4:15 PM EDT, 3:15 PM CDT, 2:15 PM MDT, and 1:15 PM PDT.
"I look forward to speaking with Herborium's shareholders during this upcoming call," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "We will discuss our new 2011 marketing plan, current product initiatives, and the significant market opportunity afforded AcnEase® by the withdrawal of Roche's Accutane®. I respectfully suggest that due to the dense subject matter, those who wish should be prepared to take notes."
Shareholder questions will also be answered during the call; shareholders are encouraged to e-mail all questions for management to herborium@smallcapss.com, any time before the call to ensure questions are covered in the time allowed.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
CONTACT: Herborium Group, Inc. Investor Relations Steve Haag (832) 413-6206
1 Year Herborium (PK) Chart |
1 Month Herborium (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions